Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
13 Leser
Artikel bewerten:
(0)

US Thyroid Cancer Market: Trends and Opportunities 2015 - 2019 Now Available at MarketReportsOnline.com

DALLAS, April 6, 2015 /PRNewswire/ --

MarketReportsOnline.com adds US Thyroid Cancer Market: Trends and Opportunities (2015 - 2019) industry research report of 75 pages published in April 2015 to the pharmaceuticals market data collection of its online business intelligence library.

Thyroid cancer, a type of malignant cancer, initiate from follicular and par follicular thyroid cells. The most effective treatment of thyroid cancer is surgical removal of thyroid gland followed by radioactive ablation and thyroid stimulating hormone (TSH) suppression therapy. Chemotherapy is also used in cases of metastasis and progressive stage of thyroid cancer. Thyroid cancer market is accelerating in the United States since 2010 and it is a disease which is fast on the rise. Incidence has more than doubled since the early 1970s, and for women, it is the cancer with the fastest-growing number of new cases.

The report titled "US Thyroid Cancer Market: Trends and Opportunities (2015-2019)" provides an insight into the overall thyroid cancer market of the United States of America. The report analyzes in detail the segments of Thyroid Cancer Market that includes Thyroid Cancer Diagnostics Surgeries, Thyroid Histopathology Market, Thyroid Cancer Secondary Surgery and Thyroid Cancer Hormone Replacement Market. The report assesses thyroid cancer types, stages and incidence rate of the disease and also discusses the factors that will result in the demand and growth of the market. Further, companies like Veracyte Inc., Mylan Inc., Forest Laboratories, Abott Laboratories and Oxigene Inc. are profiled in the report.

Product Coverage: Thyroid Cancer Diagnostic Surgeries, Thyroid Cancer Histopathology Market, Thyroid Cancer Secondary Surgery & Thyroid Cancer Hormone Replacement

FNA biopsies Company Coverage

  • Veracyte Inc.
  • Mylan Inc.
  • Forest Laboratories
  • Abott Laboratories
  • Oxigene Inc.

On the back of high incidence of thyroid cancer, it is anticipated that the thyroid cancer market in US will observe impressive double digit growth in next five years. The thyroid cancer diagnosis market is segmented into diagnostic surgeries, histopathology, secondary surgery and annual new patient hormone replacement therapy. The diagnostic technology has improved since 2011 and with use of Afirma GEC test and Afirma FNA; the detection of even minor nodules has become possible.

Purchase a copy of this research report at USD 800 (Single User License)http://www.marketreportsonline.com/contacts/purchase.php?name=404148.

Few Points from List of Tables(http://www.marketreportsonline.com/404148-toc.html)are listed below:

Figure 1: U.S Thyroid Cancer Market: 2010-2014

Figure 2: U.S Thyroid Cancer Market Segmentation: 2014

Figure 3: U.S Thyroid Cancer Market: 2015-2019

Figure 4: U.S Thyroid Cancer Diagnostic surgeries: 2010-2014- US$ Million

Figure 5: U.S Thyroid Cancer Diagnostic surgeries: 2015-2019- US$ Billion

Figure 6: U.S Thyroid Cancer Histopathology Market: 2010-2014-US$ Million

Figure 7: U.S Thyroid Cancer Histopathology Market: 2015-2019-US$ Million

Figure 8: U.S Thyroid Cancer Secondary Surgery Market: 2010-2014-US$ Million

Figure 9: U.S Thyroid Cancer Secondary Surgery Market: 2015-2019-US$ Million

Figure 10: U.S Thyroid Cancer Hormone Replacement Market: 2010-2014-US$ Million

Other Related Reports on Pharmaceuticals Market:

The US Specialty Pharmaceutical Market Report: 2015 Edition (http://www.marketreportsonline.com/404051.html) Specialty pharmaceuticals are typically high-cost, scientifically engineered drugs used to treat complex, chronic conditions that require special storage, warranting special handling, and temperature-control monitoring.

US Pharmacy Benefit Management (PBM) Industry Report: 2014 Edition (http://www.marketreportsonline.com/395328.html) The PBM providers control drug spending and utilization by virtue of their advanced tools and techniques, encouraging use of generics and other lower-cost medications.

Global Acne Treatment Market: Trends and Opportunities (2014-2019) athttp://www.marketreportsonline.com/396023.html.

About Us:

Market Reports Online provides syndicated market research reports (300,000+) and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect with Us:

G+ / Google Plus:https://plus.google.com/108330077369677148621/posts

Twitter:https://twitter.com/marketreportsol

Facebook:https://www.facebook.com/MarketReportsOnline

Contact Us:

Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@marketreportsonline.com




© 2015 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.